Drugs / SKB565
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07545265 | Jun 2026 → Dec 2028 expected | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-07-27 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Regulatory Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565 kelun-biotech.com ↗
This marks the Company's first dual-payload ADC to enter the clinical stage. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-27 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565 kelun-biotech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKB565 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07545265 ↗ |
| Route | Intravenous | “SKB565 will be administered as an intravenous (IV) infusion” NCT07545265 ↗ |